Company News: Abbott and Solvay Pharmaceuticals

Abbott completed its $6.2 billion acquisition of Solvay Pharmaceuticals, and said it expects the acquisition to add about $2.9 billion to 2010 sales, mostly outside the US, and around $500 million to the company's annual R&D investment. “In addition to taking both Abbott and Solvay products into new and expanding markets, the acquisition enhances our R&D investment, providing Abbott with the opportunity to drive future pharmaceutical growth,” said Abbott chairman and CEO Miles White in a statement.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.